Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
43
SLNO Quote, Financials, Valuation and Earnings
Last price:
$39.05
Seasonality move
:
17.65%
Day range:
$37.85 - $39.07
52-week range:
$32.63 - $90.32
Dividend yield:
0%
P/E ratio:
175.36x
P/S ratio:
10.56x
P/B ratio:
4.66x
Volume:
1.5M
Avg. volume:
1.5M
1-year change:
-13.16%
Market cap:
$2.1B
Revenue:
$190.4M
EPS (TTM):
$0.22
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SLNO
Soleno Therapeutics, Inc.
|
$88.5M | $0.08 | -- | -- | $108.92 |
|
ASRT
Assertio Holdings, Inc.
|
$6.2M | -$1.80 | -80.74% | -9.4% | $39.94 |
|
MNKD
MannKind Corp.
|
$99.9M | $0.03 | 36.67% | -59.34% | $7.94 |
|
MRKR
Marker Therapeutics, Inc.
|
$682K | -$0.19 | -69.71% | -54.94% | $7.87 |
|
NKTR
Nektar Therapeutics
|
$10.4M | -$3.50 | -5.98% | -735.41% | $129.86 |
|
RIGL
Rigel Pharmaceuticals, Inc.
|
$68.7M | $1.20 | 14.34% | 26.98% | $51.60 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SLNO
Soleno Therapeutics, Inc.
|
$39.07 | $108.92 | $2.1B | 175.36x | $0.00 | 0% | 10.56x |
|
ASRT
Assertio Holdings, Inc.
|
$11.66 | $39.94 | $74.8M | -- | $0.00 | 0% | 4.34x |
|
MNKD
MannKind Corp.
|
$3.28 | $7.94 | $1B | 195.24x | $0.00 | 0% | 2.94x |
|
MRKR
Marker Therapeutics, Inc.
|
$1.48 | $7.87 | $24.7M | -- | $0.00 | 0% | 4.01x |
|
NKTR
Nektar Therapeutics
|
$68.98 | $129.86 | $1.2B | -- | $0.00 | 0% | 71.13x |
|
RIGL
Rigel Pharmaceuticals, Inc.
|
$34.74 | $51.60 | $630.6M | 5.63x | $0.00 | 0% | 2.26x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SLNO
Soleno Therapeutics, Inc.
|
10.46% | -2.537 | 2.11% | 5.44x |
|
ASRT
Assertio Holdings, Inc.
|
29.83% | 1.367 | 53.04% | 1.43x |
|
MNKD
MannKind Corp.
|
112.08% | 0.597 | 27.19% | 1.23x |
|
MRKR
Marker Therapeutics, Inc.
|
-- | 2.111 | -- | 5.66x |
|
NKTR
Nektar Therapeutics
|
66.26% | 6.256 | 16.97% | 4.07x |
|
RIGL
Rigel Pharmaceuticals, Inc.
|
34.11% | 0.813 | 11.84% | 1.94x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SLNO
Soleno Therapeutics, Inc.
|
$90.9M | $40.4M | 5.32% | 6.16% | 44.08% | $48.6M |
|
ASRT
Assertio Holdings, Inc.
|
$30.2M | $12.9M | -18.41% | -25.86% | 26.09% | -$4.8M |
|
MNKD
MannKind Corp.
|
$78.3M | -$1.7M | 3.35% | -- | -1.49% | -$9.4M |
|
MRKR
Marker Therapeutics, Inc.
|
-- | -$2.1M | -103.04% | -103.04% | -173.31% | -$2.7M |
|
NKTR
Nektar Therapeutics
|
$11.6M | -$31.5M | -54.14% | -327.67% | -267.45% | -$48.9M |
|
RIGL
Rigel Pharmaceuticals, Inc.
|
$64.7M | $28.4M | 111.09% | 273.99% | 40.92% | $24M |
Soleno Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns SLNO or ASRT?
Assertio Holdings, Inc. has a net margin of 46.82% compared to Soleno Therapeutics, Inc.'s net margin of 23.14%. Soleno Therapeutics, Inc.'s return on equity of 6.16% beat Assertio Holdings, Inc.'s return on equity of -25.86%.
Company Gross Margin Earnings Per Share Invested Capital SLNOSoleno Therapeutics, Inc.99.06% $0.79 $502.7M ASRTAssertio Holdings, Inc.61.01% $1.61 $150.8M -
What do Analysts Say About SLNO or ASRT?
Soleno Therapeutics, Inc. has a consensus price target of $108.92, signalling upside risk potential of 179.58%. On the other hand Assertio Holdings, Inc. has an analysts' consensus of $39.94 which suggests that it could grow by 242.52%. Given that Assertio Holdings, Inc. has higher upside potential than Soleno Therapeutics, Inc., analysts believe Assertio Holdings, Inc. is more attractive than Soleno Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SLNOSoleno Therapeutics, Inc.10 0 0 ASRTAssertio Holdings, Inc.3 0 0 -
Is SLNO or ASRT More Risky?
Soleno Therapeutics, Inc. has a beta of -3.159, which suggesting that the stock is 415.852% less volatile than S&P 500. In comparison Assertio Holdings, Inc. has a beta of 0.728, suggesting its less volatile than the S&P 500 by 27.176%.
-
Which is a Better Dividend Stock SLNO or ASRT?
Soleno Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Assertio Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics, Inc. pays -- of its earnings as a dividend. Assertio Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNO or ASRT?
Soleno Therapeutics, Inc. quarterly revenues are $91.7M, which are larger than Assertio Holdings, Inc. quarterly revenues of $49.5M. Soleno Therapeutics, Inc.'s net income of $42.9M is higher than Assertio Holdings, Inc.'s net income of $11.4M. Notably, Soleno Therapeutics, Inc.'s price-to-earnings ratio is 175.36x while Assertio Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics, Inc. is 10.56x versus 4.34x for Assertio Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNOSoleno Therapeutics, Inc.10.56x 175.36x $91.7M $42.9M ASRTAssertio Holdings, Inc.4.34x -- $49.5M $11.4M
-
Which has Higher Returns SLNO or MNKD?
MannKind Corp. has a net margin of 46.82% compared to Soleno Therapeutics, Inc.'s net margin of -14.25%. Soleno Therapeutics, Inc.'s return on equity of 6.16% beat MannKind Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SLNOSoleno Therapeutics, Inc.99.06% $0.79 $502.7M MNKDMannKind Corp.69.95% -$0.05 $422.4M -
What do Analysts Say About SLNO or MNKD?
Soleno Therapeutics, Inc. has a consensus price target of $108.92, signalling upside risk potential of 179.58%. On the other hand MannKind Corp. has an analysts' consensus of $7.94 which suggests that it could grow by 159.15%. Given that Soleno Therapeutics, Inc. has higher upside potential than MannKind Corp., analysts believe Soleno Therapeutics, Inc. is more attractive than MannKind Corp..
Company Buy Ratings Hold Ratings Sell Ratings SLNOSoleno Therapeutics, Inc.10 0 0 MNKDMannKind Corp.8 1 0 -
Is SLNO or MNKD More Risky?
Soleno Therapeutics, Inc. has a beta of -3.159, which suggesting that the stock is 415.852% less volatile than S&P 500. In comparison MannKind Corp. has a beta of 0.834, suggesting its less volatile than the S&P 500 by 16.605%.
-
Which is a Better Dividend Stock SLNO or MNKD?
Soleno Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics, Inc. pays -- of its earnings as a dividend. MannKind Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNO or MNKD?
Soleno Therapeutics, Inc. quarterly revenues are $91.7M, which are smaller than MannKind Corp. quarterly revenues of $112M. Soleno Therapeutics, Inc.'s net income of $42.9M is higher than MannKind Corp.'s net income of -$15.9M. Notably, Soleno Therapeutics, Inc.'s price-to-earnings ratio is 175.36x while MannKind Corp.'s PE ratio is 195.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics, Inc. is 10.56x versus 2.94x for MannKind Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNOSoleno Therapeutics, Inc.10.56x 175.36x $91.7M $42.9M MNKDMannKind Corp.2.94x 195.24x $112M -$15.9M
-
Which has Higher Returns SLNO or MRKR?
Marker Therapeutics, Inc. has a net margin of 46.82% compared to Soleno Therapeutics, Inc.'s net margin of -162.11%. Soleno Therapeutics, Inc.'s return on equity of 6.16% beat Marker Therapeutics, Inc.'s return on equity of -103.04%.
Company Gross Margin Earnings Per Share Invested Capital SLNOSoleno Therapeutics, Inc.99.06% $0.79 $502.7M MRKRMarker Therapeutics, Inc.-- -$0.12 $18.4M -
What do Analysts Say About SLNO or MRKR?
Soleno Therapeutics, Inc. has a consensus price target of $108.92, signalling upside risk potential of 179.58%. On the other hand Marker Therapeutics, Inc. has an analysts' consensus of $7.87 which suggests that it could grow by 431.53%. Given that Marker Therapeutics, Inc. has higher upside potential than Soleno Therapeutics, Inc., analysts believe Marker Therapeutics, Inc. is more attractive than Soleno Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SLNOSoleno Therapeutics, Inc.10 0 0 MRKRMarker Therapeutics, Inc.3 0 0 -
Is SLNO or MRKR More Risky?
Soleno Therapeutics, Inc. has a beta of -3.159, which suggesting that the stock is 415.852% less volatile than S&P 500. In comparison Marker Therapeutics, Inc. has a beta of 1.419, suggesting its more volatile than the S&P 500 by 41.882%.
-
Which is a Better Dividend Stock SLNO or MRKR?
Soleno Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Marker Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics, Inc. pays -- of its earnings as a dividend. Marker Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNO or MRKR?
Soleno Therapeutics, Inc. quarterly revenues are $91.7M, which are larger than Marker Therapeutics, Inc. quarterly revenues of $1.2M. Soleno Therapeutics, Inc.'s net income of $42.9M is higher than Marker Therapeutics, Inc.'s net income of -$2M. Notably, Soleno Therapeutics, Inc.'s price-to-earnings ratio is 175.36x while Marker Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics, Inc. is 10.56x versus 4.01x for Marker Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNOSoleno Therapeutics, Inc.10.56x 175.36x $91.7M $42.9M MRKRMarker Therapeutics, Inc.4.01x -- $1.2M -$2M
-
Which has Higher Returns SLNO or NKTR?
Nektar Therapeutics has a net margin of 46.82% compared to Soleno Therapeutics, Inc.'s net margin of -301.29%. Soleno Therapeutics, Inc.'s return on equity of 6.16% beat Nektar Therapeutics's return on equity of -327.67%.
Company Gross Margin Earnings Per Share Invested Capital SLNOSoleno Therapeutics, Inc.99.06% $0.79 $502.7M NKTRNektar Therapeutics98.34% -$1.87 $252.2M -
What do Analysts Say About SLNO or NKTR?
Soleno Therapeutics, Inc. has a consensus price target of $108.92, signalling upside risk potential of 179.58%. On the other hand Nektar Therapeutics has an analysts' consensus of $129.86 which suggests that it could grow by 88.25%. Given that Soleno Therapeutics, Inc. has higher upside potential than Nektar Therapeutics, analysts believe Soleno Therapeutics, Inc. is more attractive than Nektar Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings SLNOSoleno Therapeutics, Inc.10 0 0 NKTRNektar Therapeutics7 0 0 -
Is SLNO or NKTR More Risky?
Soleno Therapeutics, Inc. has a beta of -3.159, which suggesting that the stock is 415.852% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.170, suggesting its more volatile than the S&P 500 by 16.958%.
-
Which is a Better Dividend Stock SLNO or NKTR?
Soleno Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNO or NKTR?
Soleno Therapeutics, Inc. quarterly revenues are $91.7M, which are larger than Nektar Therapeutics quarterly revenues of $11.8M. Soleno Therapeutics, Inc.'s net income of $42.9M is higher than Nektar Therapeutics's net income of -$35.5M. Notably, Soleno Therapeutics, Inc.'s price-to-earnings ratio is 175.36x while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics, Inc. is 10.56x versus 71.13x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNOSoleno Therapeutics, Inc.10.56x 175.36x $91.7M $42.9M NKTRNektar Therapeutics71.13x -- $11.8M -$35.5M
-
Which has Higher Returns SLNO or RIGL?
Rigel Pharmaceuticals, Inc. has a net margin of 46.82% compared to Soleno Therapeutics, Inc.'s net margin of 40.17%. Soleno Therapeutics, Inc.'s return on equity of 6.16% beat Rigel Pharmaceuticals, Inc.'s return on equity of 273.99%.
Company Gross Margin Earnings Per Share Invested Capital SLNOSoleno Therapeutics, Inc.99.06% $0.79 $502.7M RIGLRigel Pharmaceuticals, Inc.93.16% $1.46 $178.5M -
What do Analysts Say About SLNO or RIGL?
Soleno Therapeutics, Inc. has a consensus price target of $108.92, signalling upside risk potential of 179.58%. On the other hand Rigel Pharmaceuticals, Inc. has an analysts' consensus of $51.60 which suggests that it could grow by 48.53%. Given that Soleno Therapeutics, Inc. has higher upside potential than Rigel Pharmaceuticals, Inc., analysts believe Soleno Therapeutics, Inc. is more attractive than Rigel Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SLNOSoleno Therapeutics, Inc.10 0 0 RIGLRigel Pharmaceuticals, Inc.3 2 0 -
Is SLNO or RIGL More Risky?
Soleno Therapeutics, Inc. has a beta of -3.159, which suggesting that the stock is 415.852% less volatile than S&P 500. In comparison Rigel Pharmaceuticals, Inc. has a beta of 1.102, suggesting its more volatile than the S&P 500 by 10.219%.
-
Which is a Better Dividend Stock SLNO or RIGL?
Soleno Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics, Inc. pays -- of its earnings as a dividend. Rigel Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNO or RIGL?
Soleno Therapeutics, Inc. quarterly revenues are $91.7M, which are larger than Rigel Pharmaceuticals, Inc. quarterly revenues of $69.5M. Soleno Therapeutics, Inc.'s net income of $42.9M is higher than Rigel Pharmaceuticals, Inc.'s net income of $27.9M. Notably, Soleno Therapeutics, Inc.'s price-to-earnings ratio is 175.36x while Rigel Pharmaceuticals, Inc.'s PE ratio is 5.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics, Inc. is 10.56x versus 2.26x for Rigel Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNOSoleno Therapeutics, Inc.10.56x 175.36x $91.7M $42.9M RIGLRigel Pharmaceuticals, Inc.2.26x 5.63x $69.5M $27.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
54
AAOI alert for Mar 2
Applied Optoelectronics, Inc. [AAOI] is up 21.71% over the past day.
Buy
90
BNAI alert for Mar 2
Brand Engagement Network, Inc. [BNAI] is up 2.44% over the past day.
Sell
36
WLDN alert for Mar 2
Willdan Group, Inc. [WLDN] is down 1.93% over the past day.
